Center of Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, Health Product and Food Branch, Health Canada, Canada.
Dr. Xu Zhang obtained his Ph.D. degree in microbiology (2009-2013) at Shanghai Jiao Tong University, an M.Sc degree in microbiology (2006-2009) at Lanzhou University, and a B.Sc degree in biotechnology (2002-2004) at Lanzhou University. He obtained his postdoctoral training with Dr. Daniel Figeys at the Faculty of Medicine, University of Ottawa, Canada from 2013 to 2018. Then, he worked as a research associate at the University of Ottawa until 2021 when he moved to Health Canada as a principal investigator and research scientist leading a research laboratory on cellular immunology and mass spectrometry. Dr. Zhang has extensive research experience on the human microbiome and its interactions with therapeutics, and roles in the development of diseases, including metabolic diseases (obesity and diabetes) and inflammatory bowel disease (IBD). Dr. Zhang also has various research experience in the development of -omics approaches, including metaproteomics and metagenomics, to study the human microbiome. His current research focuses on the development and application of proteomics and metaproteomics approaches for the study of microbiota and microbiota-directed therapeutics. He has published over 50 scientific papers in journals, such as Nature Communications, Microbiome, Gut microbes, Analytical Chemistry, Molecular Cell, Journal of Proteome Research, and Journal of Proteomics.
Microbiota, Metaproteomics, Mass spectrometry, Fecal microbiota transplantation, Microbiota-directed therapeutics, Biologics